Lucas Orellana

Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study

David Adams, Michael Polydefkis, Alejandra González‐Duarte et al. · The Lancet Neurology · 2020 · 156 citations

Medicine, Neurology, Pharmacotherapy +14

Five-Year Results With Patisiran for Hereditary Transthyretin Amyloidosis With Polyneuropathy

David Adams, Jonas Wixner, Michael Polydefkis et al. · JAMA Neurology · 2025 · 31 citations · Full text

Medicine, Neurology, Pharmacotherapy +13

Role of EMSE and STESS scores in the outcome evaluation of status epilepticus

Maria Pacha, Lucas Orellana, Emanuel Silva et al. · Epilepsy & Behavior · 2016 · 27 citations

Medicine, Neurology, Neuroscience +6

Cutaneous amyloid is a biomarker in early <scp>ATTRv</scp> neuropathy and progresses across disease stages

Roy Freeman, Alejandra González‐Duarte, Fábio Barroso et al. · Annals of Clinical and Translational Neurology · 2022 · 27 citations · Full text

Medicine, Dermatology, Neurology +15

Impact of Vutrisiran on Quality of Life and Physical Function in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy

Laura Obici, Senda Ajroud‐Driss, Kon‐Ping Lin et al. · Neurology and Therapy · 2023 · 20 citations · Full text

Medicine, Neurology, Pharmacotherapy +11